301331-16-8

Basic information

• Product Name: 1-(2-NITRO-BENZENESULFONYL)-PIPERAZINE
• Synonyms: 1-(2-NITRO-BENZENESULFONYL)-PIPERAZINE
• CAS NO: 301331-16-8
• Molecular Formula: C₁₀H₁₃N₃O₄S
• Molecular Weight: 271.29
• Mol File: 301331-16-8.mol

Chemical Properties

• Melting Point: 146-148°C
• Appearance: /
• CAS DataBase Reference: 1-(2-NITRO-BENZENESULFONYL)-PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-NITRO-BENZENESULFONYL)-PIPERAZINE(301331-16-8)
• EPA Substance Registry System: 1-(2-NITRO-BENZENESULFONYL)-PIPERAZINE(301331-16-8)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 301331-16-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(2-NITRO-BENZENESULFONYL)-PIPERAZINE is used as a building block for the synthesis of various pharmaceuticals due to its ability to be incorporated into the molecular structures of potential drugs, enhancing their therapeutic effects.
Used in Agrochemical Industry:
Similarly, in the agrochemical industry, 1-(2-NITRO-BENZENESULFONYL)-PIPERAZINE is utilized as a precursor in the development of agrochemicals, contributing to the creation of effective compounds for agricultural applications.
Used in Anti-inflammatory Applications:
1-(2-NITRO-BENZENESULFONYL)-PIPERAZINE is studied for its potential as an anti-inflammatory agent, where it may be used to alleviate inflammation by modulating the body's immune response.
Used in Anticancer Applications:
It is also being investigated for its anticancer properties, where it could potentially be employed in the development of chemotherapeutic agents that target and inhibit the growth of cancer cells.
Used in Corrosion Inhibition:
1-(2-NITRO-BENZENESULFONYL)-PIPERAZINE has been explored for its use as a corrosion inhibitor, where it can be applied to metal surfaces to protect them from degradation and extend their lifespan.

Upstream product

• 110-85-0 piperazine 
• 1694-92-4 2-Nitrobenzenesulfonyl chloride 

Downstream Products

• 1136318-12-1 C₁₉H₂₃ClN₂O₄S 
• 1136790-23-2 C₁₉H₂₄N₂O₄S 
• 1177363-84-6 C₂₀H₂₆N₂O₄S 
• 1177114-50-9 C₂₀H₂₆N₂O₅S 
• 1177134-51-8 C₂₃H₂₆N₂O₄S 
• 1136778-82-9 C₁₈H₂₆N₄O₄S 
• 1136127-69-9 C₂₀H₂₆N₂O₄S 

Relevant articles and documents

Solid-Phase Polyamine Synthesis Using Piperazine and Piperidine Building Blocks

(Equation presented) Polyamines containing piperidine and piperazine moieties have been synthesized on solid support using SN2 alkylation of resin-bound secondary amines with 2-nitrobenzenesulfonates (nosylates). The effect of solvent on this a

Synthesis of Fused Diaziridine Derivatives from Cyclic Secondary Amines by Utilizing N -Bromosulfonamides as an Aminating Reagent

The synthesis of a series of fused diaziridines, which are difficult to access by existing methods, was achieved by the reaction of cyclic secondary amines with p -toluenesulfonamide in the presence of N -bromosuccinimide (NBS) and a suitable base. This o

Synthesis and antibacterial activity of novel myricetin derivatives containing sulfonylpiperazine

Myricetin derivatives containing sulfonylpiperazine were synthesized and their structures were confirmed by NMR and HRMS. The antibacterial activity results indicated that some compounds showed good antibacterial activity against Xanthomonas oryzaepv. ory

Myricetin derivative containing sulfonyl piperazine as well as preparation method and application thereof

The invention discloses a myricetin derivative containing sulfonyl piperazine as well as a preparation method and application of the myricetin derivative. The structural general formula of the myricetin derivative is shown in the specification, and n is t

Development of novel chromeno[4,3-c]pyrazol-4(2H)-one derivates bearing sulfonylpiperazine as antitumor inhibitors targeting PI3Kα

PI3K signal pathway plays a vital role in cellular functions and becomes an attractive approach for cancer therapy. Herein, a new series of novel chromeno[4,3-c]pyrazol-4(2H)-one derivatives bearing sulfonylpiperazine based on the PI3K inhibitors and our previous research. They were screened for their PI3K inhibitory activities and anticancer effects in vitro. Biological studies indicated that compound 7m revealed the remarkable antiproliferative activity (IC50 ranging from 0.03 to 0.09 μM) against four cancer cell lines (A549, Huh7, HL60 and HCT-116). Besides, compound 7m displayed a certain selective for PI3Kα (IC50 = 0.009 μM) over PI3Kβ, γ and δ, and meanwhile, it can remarkable decreased the expression level of p-Akt (Ser473) and p-S6K. In addition, compound 7m could not only induce HCT-116 cell arrest at G1 phase in a dose-dependent manner, but also induce cell apoptosis via upregulation of Bax and cleaved-caspase 3/9, and downregulation of Bcl-2. Besides, compound 7m can remarkably inhibit the growth of tumor in vivo. The above results suggested that compound 7m could be considered as a promising PI3Kα inhibitor.

Secondary amides of (R)-3,3,3-trifluoro-2-hydroxy-2-methylpropionic acid as inhibitors of pyruvate dehydrogenase kinase

N'-Methyl-N-(4-tert-butyl-1,2,5,6-tetrahydropyridine)thiourea, SDZ048- 619 (1), is a modest inhibitor (IC50 = 180 μM) of pyruvate dehydrogenase kinase (PDHK). In an optimization of the N-methylcarbothioamide moiety of 1, it was discovered that amides with a small acyl group, in particular appropriately substituted amides of (R)-3,3,3-trifluoro-2-hydroxy-2- methylpropionic acid, are inhibitors of PDHK. Utilizing this acyl moiety, herein is reported the rationale leading to the optimization of a series of acylated piperazine derivatives. Methyl substitution of the piperazine at the 2- and 5-positions (with S and R absolute stereochemistry) markedly increased the potency of the lead compound (> 1000-fold). Oral bioavailability of the compounds in this series is good and is optimal (as measured by AUC) when the 4-position of the piperazine is substituted with an electron-poor benzoyl moiety. (+)-1-N-[2,5-(S,R)-Dimethyl-4-N-(4-cyanobenzoyl)piperazine]-(R)- 3,3,3-trifluoro-2-hydroxy-2-methylpropanamide (14e) inhibits PDHK in the primary enzymatic assay with an IC50 of 16 ± 2 nM, enhances the oxidation of [14C]lactate into 14CO2 in human fibroblasts with an EC50 of 57 ± 13 nM, diminishes lactate significantly 2.5 h post-oral-dose at doses as low as 1 μmol/kg, and increases the ex vivo activity of PDH in muscle, liver, and fat tissues in normal Sprague-Dawley rats. These PDHK inhibitors, however, do not lower glucose in diabetic animal models.